Literature DB >> 6996890

The influence of renal function on plasma concentration, urinary excretion and antihypertensive effect of guanfacine.

W Kirch, H Köhler, W Braun, C von Gizycki.   

Abstract

18 hypertensive patients with a glomerular filtration rate (GFR) between 3.8 and 113ml/min received guanfacine as single intravenous and multiple oral dose treatment. Mean plasma concentrations of guanfacine on the fifth day or oral treatment ranged from 6.5 to 8.6ng/ml in patients with normal renal function (GFR > 90ml/min), as well as in those with a moderate degree of renal impairment (GFR 30 to 10ml/min) and in uraemic patients (GFR < 10ml/min). During guanfacine treatment plasma concentrations and fall in blood pressure did not differ in a statistically significant fashion among patients with varying degrees of renal function. Independent of renal function, in all investigated patients the elimination rate constant obtained from serum and urine values were close to 0.05h-1. Mean half-life of guanfacine was calculated to be 14h. The cumulative urinary excretion up to 48h fell from 57% in patients with normal renal function to 7.5% in uraemic patients. Thus, non-renal excretion plays an importat role in patients with impaired renal function.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6996890     DOI: 10.2165/00003088-198005050-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  9 in total

1.  Relationships between the release and tissue depletion of norepinephrine from the heart by guanethidine and reserpine.

Authors:  D C HARRISON; C A CHIDSEY; R GOLDMAN; E BRAUNWALD
Journal:  Circ Res       Date:  1963-03       Impact factor: 17.367

2.  Pharmacology of BS 100-141, a centrally acting antihypertensive drug.

Authors:  K Saameli; G Scholtysik; R Waite
Journal:  Clin Exp Pharmacol Physiol       Date:  1975       Impact factor: 2.557

3.  The influence of renal function on plasma levels, urinary excretion, metabolism, and antihypertensive effect of guanethidine (ismelin) in man.

Authors:  K H Rahn
Journal:  Clin Nephrol       Date:  1973 Jan-Feb       Impact factor: 0.975

4.  Diphenylhydantoin metabolism in uremia.

Authors:  J M Letteri; H Mellk; S Louis; H Kutt; P Durante; A Glazko
Journal:  N Engl J Med       Date:  1971-09-16       Impact factor: 91.245

5.  [First experiences with BS 100-141, a new antihypertensive substance].

Authors:  I Esch
Journal:  Int J Clin Pharmacol Biopharm       Date:  1976-09

6.  Substituted phenylacetylguanidines: a new class of antihypertensive agents.

Authors:  J B Bream; H Lauener; C W Picard; G Scholtysik; T G White
Journal:  Arzneimittelforschung       Date:  1975-10

7.  Pharmacological actions of the antihypertensive agent N-amidino-2-(2,6-dichlorophenyl)acetamide hydrochloride (BS 100-141).

Authors:  G Scholtysik; H Lauener; E Eichenberger; H Bürki; R Salzmann; E Müller-Schweinitzer; R Waite
Journal:  Arzneimittelforschung       Date:  1975-10

8.  Measurement of residual glomerular filtration rate in the patient receiving repetitive hemodialysis.

Authors:  J Milutinovic; R E Cutler; P Hoover; B Meijsen; B H Scribner
Journal:  Kidney Int       Date:  1975-09       Impact factor: 10.612

9.  Antihypertensive effect of N-amidino-2-(2,6-dichlorophenyl) acetamide hydrochloride. A double-blind cross-over trial versus clonidine.

Authors:  W Kirch; A Distler
Journal:  Int J Clin Pharmacol Biopharm       Date:  1978-03
  9 in total
  4 in total

1.  Guanfacine Extended-Release Tablets (Intuniv), a Nonstimulant Selective Alpha(2A)-Adrenergic Receptor Agonist For Attention-Deficit/Hyperactivity Disorder.

Authors:  Martin P Cruz
Journal:  P T       Date:  2010-08

2.  The influence of renal function on clinical pharmacokinetics of moxonidine.

Authors:  W Kirch; H J Hutt; V Plänitz
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

3.  Pharmacokinetics of guanfacine in patients undergoing haemodialysis.

Authors:  W Kirch; H Kohler; T Axthelm
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982 Oct-Dec       Impact factor: 2.441

Review 4.  Guanfacine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension.

Authors:  E M Sorkin; R C Heel
Journal:  Drugs       Date:  1986-04       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.